Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and
mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York. The company trades on NCM exchange. The company headquarter is located in New York, United States. The company was established in the 2016.
| Ticker | PTIX |
| Long Name | Protagenic Therapeutics, Inc. |
| Short Name | Protagenic Therapeutics, Inc. |